Semaglutide
A GLP-1 receptor agonist used in FDA-approved products for type 2 diabetes, chronic weight management, and additional labeled uses depending on brand and indication.
Also referenced as: Ozempic, Wegovy, Rybelsus
What has the price actually done?
Daily, exact-comparability offers. Discounts use the terms known on each historical date.
How this history is calculated
Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.
Let the market come to you.
Watch the best market price or one vendor. Get one email when CP-1S crosses your target, drops, or sets a new tracked low—without daily noise.
This peptide maps to at least one regulated medical product or label context in the United States.
This profile is grouped by its dominant research area, not by vendor shelf placement.
Ozempic, Wegovy, Rybelsus
FDA label signal · 779 trials · 5534 PubMed results
Semaglutide is an FDA-approved medicine with substantial published trial evidence. Note that research-market products sold under this name are not the approved medicine and are not held to the same manufacturing or labeling standards.
Semaglutide has 59 name-matched clinical trials (3 international) (highest phase: Phase 4) and 5541 PubMed-indexed publications and holds an FDA drug label. 9 trials have posted results.
Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-09-08 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What semaglutide is
Semaglutide is a GLP-1 receptor agonist used in branded prescription products including Ozempic, Wegovy, and Rybelsus. The approved indication depends on the product and label, but semaglutide is now central to both diabetes care and chronic weight-management treatment in the United States.
Why it matters
Semaglutide helped define the current GLP-1 era because it pushed appetite control and weight-loss pharmacology into the mainstream. It is also one of the clearest examples of why brand, indication, and formulation matter more than the ingredient name alone.
Regulatory context
FDA has approved semaglutide in different branded products for different uses. Relevant official FDA pages include:
- Wegovy cardiovascular-risk supplement approval (NDA 215256/S-011)
- FDA concerns with unapproved GLP-1 drugs
That distinction matters because unapproved or compounded products are not interchangeable with labeled FDA-approved products.
Practical reading note
When people say “semaglutide,” they may be talking about:
- diabetes treatment
- chronic weight management
- off-label use
- compounded or research-market material
Those are not the same category of product or risk profile.
What to watch
If you are researching semaglutide, the important questions are usually:
- which branded or unbranded product is actually being discussed
- whether the use is on-label or off-label
- whether the product is FDA-approved, compounded, or sold outside regulated medical channels
That framing is often more useful than repeating hype-cycle language about miracle weight-loss drugs.